From Yahoo Finance: 2025-03-23 09:30:00

Sarepta Therapeutics shares dropped 20% in one day after news of a patient on its Elevidys gene therapy suffering fatal acute liver failure. The therapy, approved for ambulatory DMD patients, is under accelerated approval for non-ambulatory patients, needing further efficacy confirmation in clinical trials.

The patient had recently suffered a cytomegalovirus infection, which could have contributed to the liver failure. With Elevidys accounting for over 50% of Sarepta’s revenue, investors are concerned about the impact on sales and the potential regulatory actions.

While Sarepta has other DMD treatments in development, Elevidys was expected to be its main growth driver. The uncertainty surrounding the treatment’s future makes the company’s shares risky. Investors comfortable with risk may consider a small position, while others may look elsewhere in the biotech industry.

Read more: Is This Stock a Buy After a Massive 20% Drop in 1 Day?